Effect of metformin administration and weight loss on plasma ceramide C16:0, C18:0, C24:1 concentrations in patients with non-alcoholic fatty liver disease associated with insulin resistance and type 2 diabetes

Authors

  • L.L. Pavlovskyi Bogomolets National Medical University, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.54.2.2020.206227

Keywords:

non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, ceramides

Abstract

Background. Ceramides are the fats of the sphingolipid family that are involved in the development of insulin resistance, non-alcoholic fatty liver disease, and type 2 diabetes. Despite the standards of treatment for these diseases, there is currently a lack of information regarding their effect on the concentration of ceramides in blood plasma. In this regard, we investigated how metformin administration and weight loss affect the concentrations of ceramides C16:0, C18:0, C24:1 in these patients. The purpose was to study and compare the plasma concentrations of ceramides C16:0, C18:0, C24:1 in patients with non-alcoholic fatty liver disease before and after treatment. Materials and methods. The study involved 50 patients with non-alcoholic fatty liver disease, who were divided into two groups: 24 people with insulin resistance and 27 with type 2 diabetes. As a treatment for patients with insulin resistance, it was recommended to lose weight. Patients with type 2 diabetes received metformin at a dose of 500 mg 2 times a day. The control group consisted of 10 healthy individuals. Ceramides were determined by liquid chromatography with mass spectrometry (Shimadzu Nexera X2 UHPLC, Shimadzu LCMS-8045 mass spectrometer). Results. When evaluating the concentrations of ceramides C16:0, C18:0, C24: 1 in both groups, a significant increase was found compared to the control group (p < 0.001). After treatment, patients in both groups showed a significant decrease in ceramide concentration (p < 0.001). In addition, it was found that C16:0, C18:0, C24:1 ceramide fractions correlated with the main laboratory and instrumental parameters in both groups. Conclusions. In patients with non-alcoholic fatty liver disease, insulin resistance, and type 2 diabetes, the concentration of C16:0, C18:0, C24:1 ceramides was increased. Against the background of appropriate treatment, ceramide level has decreased.

Downloads

Download data is not yet available.

References

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73‐84. doi:10.1002/hep.28431.

Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793‐801. doi:10.1016/j.jhep.2019.06.021.

Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330‐344. doi:10.1038/nrgastro.2013.41.

Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15(4):249‐274. doi:10.1038/nrd.2015.3.

Chaurasia B, Summers SA. Ceramides - Lipotoxic Inducers of Metabolic Disorders. Trends Endocrinol Metab. 2015;26(10):538‐550. doi:10.1016/j.tem.2015.07.006.

Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab. 2012;15(5):585‐594. doi:10.1016/j.cmet.2012.04.002.

Galadari S, Rahman A, Pallichankandy S, Galadari A, Thayyullathil F. Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids Health Dis. 2013;12:98. doi:10.1186/1476-511X-12-98.

Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2012;23(8):365‐371. doi:10.1016/j.tem.2012.04.005.

Colombini M. Ceramide channels and their role in mitochondria-mediated apoptosis. Biochim Biophys Acta. 2010;1797(6-7):1239‐1244. doi:10.1016/j.bbabio.2010.01.021.

Kasumov T, Huang H, Chung YM, Zhang R, McCullough AJ, Kirwan JP. Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem. 2010;401(1):154‐161. doi:10.1016/j.ab.2010.02.023.

Apostolopoulou M, Gordillo R, Koliaki C, et al. Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis. Diabetes Care. 2018;41(6):1235‐1243. doi:10.2337/dc17-1318.

Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58(2):337‐343. doi:10.2337/db08-1228.

Kasumov T, Solomon TP, Hwang C, et al. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring). 2015;23(7):1414‐1421. doi:10.1002/oby.21117.

Zabielski P, Hady HR, Chacinska M, Roszczyc K, Gorski J, Blachnio-Zabielska AU. The effect of high fat diet and metformin treatment on liver lipids accumulation and their impact on insulin action. Sci Rep. 2018;8(1):7249. doi:10.1038/s41598-018-25397-6.

Zabielski P, Chacinska M, Charkiewicz K, Baranowski M, Gorski J, Blachnio-Zabielska AU. Effect of metformin on bioactive lipid metabolism in insulin-resistant muscle. J Endocrinol. 2017;233(3):329‐340. doi:10.1530/JOE-16-0381.

Downloads

Published

2021-09-06

How to Cite

Pavlovskyi, L. (2021). Effect of metformin administration and weight loss on plasma ceramide C16:0, C18:0, C24:1 concentrations in patients with non-alcoholic fatty liver disease associated with insulin resistance and type 2 diabetes. GASTROENTEROLOGY, 54(2), 96–100. https://doi.org/10.22141/2308-2097.54.2.2020.206227

Issue

Vol. 54 No. 2 (2020)

Section

Original Researches

License

Copyright (c) 2020 L.L. Pavlovskyi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.